Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Simcere Pharmaceutical GroupSMHGF 94 Net Current Asset Value is $0.11 as of Dec. 2025, which is 99% below its 10-year median of 15.47. GuruFocus rates SMHGF with a GF Score™ of 94/100 and a GF Value™ of $1.26. Among 609 Drug Manufacturers companies, Simcere Pharmaceutical Group ranks worse than 79.31% on this metric.
In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).
Simcere Pharmaceutical Group's net current asset value per share for the quarter that ended in Dec. 2025 was $0.11.
The historical rank and industry rank for Simcere Pharmaceutical Group's Net Current Asset Value or its related term are showing as below:
SMHGF'
s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 8.01 Med: 15.47 Max: 24.32
Current: 14.89
During the past 9 years, the highest Price-to-Net-Current-Asset-Value Ratio of Simcere Pharmaceutical Group was 24.32. The lowest was 8.01. And the median was 15.47.
SMHGF's Price-to-Net-Current-Asset-Value is ranked worse than 79.31% of 609
companies
in the Drug Manufacturers industry
Industry Median: 5.67
vs SMHGF: 14.89
Simcere Pharmaceutical Group (OTCPK:SMHGF) Net Current Asset Value Explanation
Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."
The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]
Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.
One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Grahams strategy produced similar results.
Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.
Simcere Pharmaceutical Group Net Current Asset Value Related Terms
Simcere Pharmaceutical Group Net Current Asset Value Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Simcere Pharmaceutical Group Net Current Asset Value Chart
SMHGF vs ZTS, UTHR: Net Current Asset Value Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Simcere Pharmaceutical Group's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Simcere Pharmaceutical Group Price-to-Net-Current-Asset-Value vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Simcere Pharmaceutical Group's Price-to-Net-Current-Asset-Value distribution charts can be found below:
* The bar in red indicates where Simcere Pharmaceutical Group's Price-to-Net-Current-Asset-Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Net Current Asset Value of $0.11 mean?
Simcere Pharmaceutical Group (SMHGF) has a Net Current Asset Value of $0.11 as of Dec. 2025. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Simcere Pharmaceutical Group and its competitors. This is 99% below median its historical median of 15.47. Over the past decade, Simcere Pharmaceutical Group's Net Current Asset Value has ranged from 8.01 to 24.32. According to the industry distribution chart, Simcere Pharmaceutical Group ranks #483 out of 609 companies in the Drug Manufacturers industry, placing it in the top 79.3%.
Is Simcere Pharmaceutical Group's Net Current Asset Value too high?
Simcere Pharmaceutical Group's current Net Current Asset Value of $0.11 is 99% below median its 10-year median of 15.47. Over the past 10 years, this metric has ranged from a low of 8.01 to a high of 24.32. The Drug Manufacturers industry median Net Current Asset Value is 5.67. Simcere Pharmaceutical Group's value of $0.11 is 98.1% below this industry median. Based on the distribution chart, Simcere Pharmaceutical Group ranks #483 out of 609 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Simcere Pharmaceutical Group has a GF Score™ of 94/100, reflecting its overall financial health beyond just this single metric.
How does Simcere Pharmaceutical Group's Net Current Asset Value compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Simcere Pharmaceutical Group ranks #483 out of 609 companies for Net Current Asset Value. This places Simcere Pharmaceutical Group in the lower half of its industry. The industry median Net Current Asset Value is 5.67. Simcere Pharmaceutical Group's value of $0.11 is 98.1% below this benchmark. Historically, Simcere Pharmaceutical Group's own Net Current Asset Value has ranged from 8.01 to 24.32 over the past decade. While the company's 10-year median is 15.47 vs. the industry median of 5.67, Simcere Pharmaceutical Group has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Current Asset Value for a Drug Manufacturers company?
The median Net Current Asset Value among Drug Manufacturers companies is 5.67, based on 609 companies in the industry. Companies in the top quartile (top 25%) have a Net Current Asset Value significantly above this median, while those in the bottom quartile fall well below. However, Net Current Asset Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Simcere Pharmaceutical Group's current Net Current Asset Value of $0.11 is 98.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Current Asset Value mean?
A high Net Current Asset Value can signal that a stock is expensive relative to its fundamentals. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Simcere Pharmaceutical Group and its competitors. For the Drug Manufacturers industry, the median Net Current Asset Value is 5.67 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Simcere Pharmaceutical Group's current Net Current Asset Value is $0.11, which is 99% below median its own 10-year median of 15.47. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Simcere Pharmaceutical Group stock overvalued right now?
Simcere Pharmaceutical Group (SMHGF) has a current Net Current Asset Value of $0.11. The stock's GF Value™ is $1.26, compared to a current price of $1.49 — trading 18.2% above its estimated fair value. The current Net Current Asset Value is $0.11, which is 99% below median its 10-year median of 15.47 and 98.1% below the Drug Manufacturers industry median of 5.67. Simcere Pharmaceutical Group's overall GF Score™ is 94/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Current Asset Value calculated?
Net Current Asset Value is calculated from a company's financial statements. For Simcere Pharmaceutical Group (SMHGF), the current Net Current Asset Value is $0.11 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Simcere Pharmaceutical Group (SMHGF) Overvalued in 2026?
Based on GuruFocus' analysis, Simcere Pharmaceutical Group stock appears to be overvalued.
The current stock price of $1.49 is trading 18.2% above its estimated GF Value™ of $1.26.
Key valuation signals for SMHGF:
Net Current Asset Value: $0.11 (99% below median its 10-year median of 15.47)
GF Value™: $1.26 vs. price of $1.49 (18.2% above fair value)
Industry Position: 98.1% below the Drug Manufacturers median (#483 of 609)
No single metric tells the full story. See the SMHGF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Simcere Pharmaceutical Group Ltd is engaged in the R&D, production, and commercialization of pharmaceuticals focused on generic pharmaceuticals. The company has a diversified product portfolio focused on therapeutic areas, including, neuroscience, anti-oncology, autoimmune, and antiinfection. The company's products include Endostar, Enweida, Enzeshu, Iremod, Quviviq, Cosela, Sanbexin and Others.
94GF Score
Get the complete analysis for SMHGF
Net Current Asset Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SMHGF has been successfully added to your 
